JAMA 16 Nov 2011 Vol 306 2099 Steve Nissen became something of a hero of mine when he showed how bad data from pharma-funded studies had been used to mask the fact that rosiglitazone (Avandia) was harming diabetic patients while lowering a surrogate end-point – blood glucose or glycated haemoglobin. But here he is leading […]
Richard Lehman’s journal review – 21 November 2011